According to the latest company announcement, Sandu Pharmaceuticals Board of Directors met on August 11, 2026, approving the unaudited standalone financial results for the quarter ended June 30, 2026. The company has set September 4, 2026 as the record date for determining dividend eligibility for the financial year ended March 31, 2026. The 41st Annual General Meeting (AGM) has been scheduled for September 11, 2026 at 4:30 PM IST via Video Conferencing/Other Audio-Visual Means. The Board also recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a first term of five consecutive years from the conclusion of the upcoming AGM until AGM 2031, subject to member approval.
According to reports from Business Standard, Sandu Pharmaceuticals delivered mixed financial results for the quarter ended June 2026. The company's standalone net profit increased by 4.55% to ₹0.23 crore compared to ₹0.22 crore in the corresponding quarter of the previous year. The latest unaudited results show profit before tax of ₹36.05 lakhs and profit for the period of ₹22.82 lakhs. The company's comprehensive income for the period, net of tax, was ₹38.35 lakhs. This modest profit growth came despite facing revenue challenges during the quarter, with the company maintaining consistent profitability improvement across quarters.
As reported by Business Standard, the company's sales declined by 1.86% to ₹16.39 crore in Q1 FY2026-27, down from ₹16.70 crore in the same quarter of the previous financial year. According to the latest unaudited results, revenue was ₹164.06 million compared to ₹167.17 million a year ago, representing a slight decline from the previous year. This revenue contraction created pressure on the company's overall performance, though the company managed to maintain profitability through operational efficiency improvements and cost management initiatives.
The company's basic earnings per share from continuing operations improved significantly to ₹0.37 compared to ₹0.23 a year ago, as reported in the latest unaudited results. Similarly, diluted earnings per share from continuing operations was ₹0.37 compared to ₹0.23 a year ago, indicating strong earnings growth despite revenue headwinds. This substantial improvement in earnings per share demonstrates the company's ability to enhance profitability through operational efficiency and cost management initiatives, with the latest results confirming consistent EPS growth across quarters.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) improved to 3.23% in the June 2026 quarter compared to 3.17% in the corresponding quarter of the previous year. Additionally, PBDT remained stable at ₹0.52 crore and PBT increased by 6% to ₹0.36 crore from ₹0.34 crore in the previous year's quarter. The company has approved the closure of its Register of Members and Share Transfer Books from Friday, September 4, 2026 to Friday, September 11, 2026, inclusive. The Board also recommended seeking member approval for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited at the upcoming AGM.
